CNS Drugs

, Volume 10, Issue 3, pp 181–188 | Cite as

Treatment of Lennox-Gastaut Syndrome

Current Recommendations
  • Norman Delanty
  • Jacqueline French
Disease Management


Lennox-Gastaut syndrome (LGS) is a complex epilepsy of childhood characterised by an EEG demonstrating slow spike and wave complexes, multiple seizure types and cognitive impairment.

Control of seizures is difficult, and the effectiveness of established anticon-vulsants is often disappointing. In the past few years, many new medications have been introduced for the treatment of partial epilepsy in adults. Emerging evidence suggests that some of these agents are also useful in LGS.

Felbamate has been shown to be effective in a large controlled clinical trial, although its use is limited by life-threatening idiosyncratic reactions. Lamotrigine and topiramate have recently been shown in prospective controlled trials to be beneficial and well tolerated in patients with LGS. Vigabatrin appears to be particularly useful in children with underlying tuberous sclerosis. Novel neuroprotective strategies may be tested in the near future.

The ketogenic diet has empirical efficacy in some children with intractable seizures. Vagal nerve stimulation is currently being tested in LGS, and preliminary data are encouraging. Anterior callosotomy may provide an improved quality of life in children with frequent ‘drop attacks’.

These pharmacological and nonpharmacological approaches to the treatment of LGS offer new hope to patients and their families.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lennox WG. The petit mal epilepsies: their treatment with tridione. JAMA 1945; 129: 1069–74CrossRefGoogle Scholar
  2. 2.
    Gastaut H, Roger J, Soulayrol R, et al. Childhood epileptic encephalopathy with diffuse slow spike waves (otherwise known as ‘petit mal variant’) or Lennox syndrome. Epilepsia 1966; 7: 139–79CrossRefGoogle Scholar
  3. 3.
    Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389–99CrossRefGoogle Scholar
  4. 4.
    Aicardi J. Epileptic encephalopathies of early childhood. Curr Opin Neurol Neurosurg 1992; 5: 344–8PubMedGoogle Scholar
  5. 5.
    Dulac O, N’Guyen T. The Lennox-Gastaut syndrome. Epilepsia 1993; 34Suppl. 7: S7–17PubMedCrossRefGoogle Scholar
  6. 6.
    Glauser TA. Pediatric epilepsy syndromes. Curr Opin Pediatr 1995; 7: 640–9PubMedGoogle Scholar
  7. 7.
    Bednarek N, Motte J, Soukfflet C, et al. Evidence of late-onset infantile spasms. Epilepsia 1998; 39: 55–60PubMedCrossRefGoogle Scholar
  8. 8.
    Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities: III. U.S. experience since 1986. Neurology 1996; 46: 465–9PubMedCrossRefGoogle Scholar
  9. 9.
    Dimario FJ, Clancy RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr Neurol 1988; 4: 249–51PubMedCrossRefGoogle Scholar
  10. 10.
    Munn R, Farrell K. Open study of clobazam in refractory epilepsy. Pediatr Neurol 1993; 9: 465–9PubMedCrossRefGoogle Scholar
  11. 11.
    Farrell K. Symptomatic generalized epilepsy and Lennox-Gastaut syndrome. In: Wyllie E, editor. The treatment of epilepsy: principles and practice. 2nd ed. Baltimore: Williams and Wilkins, 1996: 530–9Google Scholar
  12. 12.
    Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia 1989; 30: 422–9CrossRefGoogle Scholar
  13. 13.
    Gram L. Pharmacokinetics of new antiepileptic drugs. Epilepsia 1996; 37Suppl. 6: S12–6PubMedCrossRefGoogle Scholar
  14. 14.
    Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041–65PubMedCrossRefGoogle Scholar
  15. 15.
    Felbamate Study Group in Lennox-Gaustaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29–33CrossRefGoogle Scholar
  16. 16.
    Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993; 34Suppl. 7: S18–24PubMedCrossRefGoogle Scholar
  17. 17.
    Bourgeois BF. Felbamate. Semin Pediatr Neurol 1997; 4: 3–8PubMedCrossRefGoogle Scholar
  18. 18.
    Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37Suppl. 6: S4–11PubMedCrossRefGoogle Scholar
  19. 19.
    Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995; 26: 117–22PubMedCrossRefGoogle Scholar
  20. 20.
    Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359–67PubMedCrossRefGoogle Scholar
  21. 21.
    Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox-Gastaut syndrome). Epilepsia 1997; 38: 68–73PubMedCrossRefGoogle Scholar
  22. 22.
    Farrell K, Connolly MB, Munn R, et al. Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. Pediatr Neurol 1997; 16: 201–5PubMedCrossRefGoogle Scholar
  23. 23.
    Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997; 337: 1807–12PubMedCrossRefGoogle Scholar
  24. 24.
    Wadelius M, Karlsson T, Wadelius C, et al. Lamotrigine and toxic epidermal necrolysis [letter]. Lancet 1996; 348: 1041PubMedCrossRefGoogle Scholar
  25. 25.
    Mitchell P. Paediatric lamotrigine use hit by rash reports [news]. Lancet 1997; 349: 1080CrossRefGoogle Scholar
  26. 26.
    Besag FM, Dulac O, Alving J, et al. Long-term safety and efficacy of lamotrigine (Lamictal) in pediatric patients with epilepsy. Seizure 1997; 6: 51–6PubMedCrossRefGoogle Scholar
  27. 27.
    French JA, Bourgeois BFD, Dreifus FE, et al. An open-label multicenter study of topiramate in patients with the Lennox-Gastaut syndrome [abstract]. Neurology 1995; 45Suppl. 4: A250Google Scholar
  28. 28.
    Glauser TA. Preliminary observations on topiramate in pediatric epilepsies. Epilepsia 1997; 38Suppl. 1: S37–41PubMedCrossRefGoogle Scholar
  29. 29.
    Guerreiro MM, Manreza ML, Guerreiro CA, et al. A pilot study of topiramate in children with Lennox-Gastaut syndrome [abstract]. Neurology 1997; 48 Suppl.: A39CrossRefGoogle Scholar
  30. 30.
    Fisher R, Blum D. Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Epilepsia 1995; 36Suppl. 2: S105–14PubMedCrossRefGoogle Scholar
  31. 31.
    Feucht M, Brantner-Inthaler S. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia 1994; 35: 993–8PubMedCrossRefGoogle Scholar
  32. 32.
    Gibbs J, Appleton RE, Rosenbloom L. Vigabatrin in intractable childhood epilepsy: a retrospective study. Pediatr Neurol 1992; 8: 338–40PubMedCrossRefGoogle Scholar
  33. 33.
    Appleton RE. Vigabatrin in the management of generalized seizures in children. Seizure 1995; 4: 45–8PubMedCrossRefGoogle Scholar
  34. 34.
    Lopez-Valdes E, Hernandez-Lain A, Simon R, et al. Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients [in Spanish]. Rev Neurol 1996; 24: 1255–7PubMedGoogle Scholar
  35. 35.
    Shields WD, Sanker R. Vigabatrin. Semin Pediatr Neurol 1997; 4: 43–50PubMedCrossRefGoogle Scholar
  36. 36.
    Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26: 389–95PubMedCrossRefGoogle Scholar
  37. 37.
    Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989; 27Suppl. 1: 43S–5SPubMedCrossRefGoogle Scholar
  38. 38.
    Mauguiere F, Chauvel P, Dewailly J, et al. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 1997; 39: 301–8CrossRefGoogle Scholar
  39. 39.
    Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614–8PubMedCrossRefGoogle Scholar
  40. 40.
    Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760–87PubMedCrossRefGoogle Scholar
  41. 41.
    Sakamato K, Kurokawa T, Tomita S, et al. Effects of zonisamide in children with epilepsy. Curr Ther Res 1988; 43: 378–83Google Scholar
  42. 42.
    Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996; 46: 852–3PubMedCrossRefGoogle Scholar
  43. 43.
    Duse M, Notarangelo LD, Tiberti S, et al. Intravenous immune globulin in the treatment of intractable childhood epilepsy. Clin Exp Immunol 1996; 104Suppl. 1: 71–6PubMedGoogle Scholar
  44. 44.
    van Engelen BGM, Renier WO, Weemaes CMR, et al. Highdose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome: an add-on study. Eur J Pediatr 1994; 153: 762–9PubMedCrossRefGoogle Scholar
  45. 45.
    Ilium N, Taudorf K, Heilmann C, et al. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics 1990; 21: 87–90CrossRefGoogle Scholar
  46. 46.
    Gross-Tsur V, Shalev RS, Kazir E, et al. Intravenous high-dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand 1993; 88: 204–9PubMedCrossRefGoogle Scholar
  47. 47.
    Wheless JW. The ketogenic diet: fa(c)t or fiction. J Child Neurol 1995; 10: 419–23PubMedCrossRefGoogle Scholar
  48. 48.
    Nordli Jr DR, De Vivo DC. The ketogenic diet revisited: back to the future. Epilepsia 1997; 38: 743–9PubMedCrossRefGoogle Scholar
  49. 49.
    Kinsman SL, Vining EP, Quaskey SA, et al. Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases. Epilepsia 1992; 33: 1132–6PubMedCrossRefGoogle Scholar
  50. 50.
    Fisher RS, Krauss GL, Ramsey E, et al. Assessment of vagus nerve stimulation for epilepsy: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 1997; 49: 293–7PubMedCrossRefGoogle Scholar
  51. 51.
    Hornig GW, Murphy JV, Schallert G, et al. Left vagus nerve stimulation in children with refractory epilepsy. South Med J 1997; 90: 484–8PubMedCrossRefGoogle Scholar
  52. 52.
    Chugani HT, Shewmon DA, Shields WD, et al. Surgery for intractable infantile spasms: neuroimaging perspectives. Epilepsia 1993; 34: 764–71PubMedCrossRefGoogle Scholar
  53. 53.
    Chugani HT. The role of PET in childhood epilepsy. J Child Neurol 1994; 9Suppl. 1: S82–8PubMedCrossRefGoogle Scholar
  54. 54.
    Sakas DE, Philips J. Anterior callosotomy in the management of intractable epileptic seizures: significance of the extent of resection. Acta Neurochir 1996; 138: 700–7CrossRefGoogle Scholar
  55. 55.
    Minguez-Castellanos A, Sanchez-Alvarez JC, Altuzarra A, et al. Callosotomy in the treatment of drug-resistant epilepsy [in Spanish]. Rev Neurol 1996; 24: 539–48PubMedGoogle Scholar
  56. 56.
    Schwartkroin PA. Origins of the epileptic state. Epilepsia 1997; 38: 853–8CrossRefGoogle Scholar
  57. 57.
    Davies JA. Remacemide hydrochloride: a novel antiepileptic agent. Gen Pharmacol 1997; 28: 499–502PubMedCrossRefGoogle Scholar
  58. 58.
    Hurd RW, Wilder BJ, Helveston WR, et al. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology 1996; 47: 1264–8PubMedCrossRefGoogle Scholar
  59. 59.
    van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Norman Delanty
    • 1
  • Jacqueline French
    • 1
  1. 1.Department of NeurologyHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations